Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.2 billion in the period from 7 May 2024 to 5 August 2024.

Since the announcement 17 May 2024, the following transactions have been made:

  Number ofB shares Averagepurchase price Transactionvalue, DKK
Accumulated, last announcement 242,000   218,194,459
17 May 2024 38,952 906.86 35,324,002
21 May 2024 40,000 917.94 36,717,473
22 May 2024 38,200 916.60 35,014,181
23 May 2024 39,000 937.21 36,551,013
24 May 2024 38,000 930.99 35,377,758
Accumulated under the programme 436,152   397,178,886

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 10,535,966 B shares of DKK 0.10 as treasury shares, corresponding to 0.2% of the share capital. The total amount of A and B shares in the company is 4,446,500,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 24 May 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 9,170,402 B shares at an average share price of DKK 864.18 per B share equal to a transaction value of DKK 7,924,913,659.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.                            

Contact for further information.

Media:  
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com  Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com 
Investors:  
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com  Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com 
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com  Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com 
Sina Meyer +45 3079 6656azey@novonordisk.com  Frederik Taylor Pitter +45 3075 8259fptr@novonordisk.com 
Ida Melvold Gjøsund+45 3077 5649 idmg@novonordisk.com   

Company announcement No 44 / 2024

Attachments

  • CA20240527 Safe Harbour
  • 20240527 safe harbour transaction details
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Novo Nordisk Charts.